Table 2 Clinical characteristics of patients in the Covid-Ser-Vac study

From: Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination

 

Heterologous vaccine

Homologous vaccine

P value

Adjusted P value

 

(n = 29)

(n = 31)

Male sex (n (%))

9 (31.03)

8 (25.80)

0.7742

0.7742

Age in years (median (IQR))

34 (27–40)

41 (33–52)

0.0016

0.0056

Body mass index1 (n)

28

31

  

Median (IQR)

22.25 (20.7–24.3)

23.12 (21.45–25.83)

0.2279

0.3988

Currently smoker (n (%))

5 (17.24)

8 (25.8)

0.5358

0.6251

Alcohol consumption1 (n (%))

7 (24.13)

5 (16.12)

0.5269

0.6251

Delay between two vaccine doses

    

Median (IQR)

85 (84–85)

29 (26–31)

<0.0001

0.0007

Delay between second vaccine dose and third blood sample

    

Median (IQR)

30 (28;34)

28 (27;31)

0.0245

0.057

Presence of comorbiditya (n (%))

0

0

NA

NA

  1. Comorbidities include neurological disorders, cardiovascular disorders, hypertension, heart failure, diabetes, immune deficiency, liver disease, kidney disease, cancer, hypothyroid or rheumatic disease. For alcohol consumption, this was defined as consumption at least once a week. NA, not applicable.
  2. Mann–Whitney and Fisher two-sided tests were used for quantitative and qualitative variables (in italic), respectively. Adjusted P values were calculated using the Benjamini–Hochberg method.
  3. aIndicates one missing data.
Back to article page